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the position of the target site for 
engineered nucleases improves the 
aberrant mRnA clearance in in vivo 
genome editing
Jae Hoon Lee1,6, Sungsook Yu2,6, Tae Wook nam1,6, Jae-il Roh1, Young Jin1, Jeong Pil Han3,  
Ji-Young cha4, Yoon Ki Kim  5, Su-Cheong Yeom  3, Ki Taek nam  2* & Han-Woong Lee1*
engineered nucleases are widely used for creating frameshift or nonsense mutations in the target 
genes to eliminate gene functions. the resulting mRnAs carrying premature termination codons can 
be eliminated by nonsense-mediated mRNA decay. However, it is unclear how effective this process 
would be in vivo. Here, we found that the nonsense-mediated decay was unable to remove the mutant 
mRnAs in twelve out of sixteen homozygous mutant mice with frameshift mutations generated 
using engineered nucleases, which is far beyond what we expected. The frameshift mutant proteins 
translated by a single nucleotide deletion within the coding region were also detected in the p53 mutant 
mice. Furthermore, we showed that targeting the exons present downstream of the exons with a 
start codon or distant from ATG is relatively effective for eliminating mutant mRNAs in vivo, whereas 
the exons with a start codon are targeted to express the mutant mRnAs. of the sixteen mutant mice 
generated, only four mutant mice targeting the downstream exons exhibited over 80% clearance of 
mutant mRNAs. Since the abnormal products, either mutant RNAs or mutant proteins, expressed by 
the target alleles might obscure the outcome of genome editing, these findings will provide insights in 
the improved performance of engineered nucleases when they are applied in vivo.
Engineered nucleases such as clustered regularly interspaced short palindromic repeats/CRISPR-associated pro-
tein 9 (CRISPR/Cas9) and transcription activator-like effector nucleases (TALENs) are versatile tools for gene 
knockout1,2. These tools are commonly designed to cleave immediately downstream of a translation initiation 
codon (ATG) in the open reading frame (ORF) of target genes1–5. The double-strand breaks generated by cleav-
ing DNA cause insertion/deletion (indel) mutations at the target site as a result of non-homologous end join-
ing (NHEJ)-mediated DNA repair5,6. These mutations introduce premature termination codons (PTCs) in the 
ORF of target genes7,8, leading to mutant mRNA degradation by the nonsense-mediated mRNA decay (NMD)9. 
Therefore, the tools have been used to create and edit various model organisms, which provide evidence for the 
clinical use of the engineered nucleases3,4. Currently, the engineered nucleases are being developed as a therapy 
for treating diseases by eliminating the causative genes with harmful mutations10. However, more research is 
required to understand their effects on the treatment of the diseases.
NMD, an mRNA surveillance mechanism, largely eliminates the aberrant mRNAs containing PTCs to pre-
vent the expression of truncated and potentially harmful mutant proteins9. Usually, the exon junction complexes 
(EJCs) bound to 20–24 bp upstream of the exon-exon junctions of mRNAs are removed by the ribosomes trans-
lating the mRNAs9,11. However, EJCs remain bound to the PTC-harboring mRNAs since the ribosomes trans-
lating the mRNAs stop when they reach the PTC, leading to the decay of the mRNAs through communication 
between the mRNA-binding EJCs and the ribosomes9,11. Therefore, it is widely accepted that mRNAs with the 
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PTC in the last exon or single exon can be excluded from the decay since they do not have an EJC as a transla-
tional termination codon that is typically located in the last exon of a gene9. In addition, the mRNAs with PTCs 
located in close proximity to the AUG start codon are expected to bypass NMD owing to the AUG-proximity 
effect, which is probably a result of translational reinitiation initiated by the post-termination ribosomes down-
stream of the AUG codon9,12. However, it remains unclear how much mutant mRNAs generated from the alleles 
with frameshift mutations are eliminated in vivo and whether the mutant mRNAs can be translated.
This study reveals that the PTC-harboring mRNAs are frequently expressed in the mutant mice generated 
using the engineered nucleases such as CRISPR/Cas9 and TALENs. Specifically, the mutant p53 protein generated 
from the targeted allele was observed in our p53 mutant mice. Furthermore, the amount of detectable mutant 
mRNAs in various mutant mice was influenced by the position of mutation in the ORFs. Collectively, our findings 
will provide insights in the selection of a therapeutic target site using the engineered nucleases, thereby improving 
the current gene therapies based on PTC-mediated gene disruption using genome editors, such as Zinc-finger 
nucleases, TALENs, CRISPR/Cas9, and CRISPR based-editors.
Results
Mutant mRnAs are frequently expressed in mutant mice created by the engineered nucle-
ases. To generate sixteen knockout mice for thirteen genes by inducing indel-mediated frameshift mutations, 
we designed gRNAs and TALENs targeting the downstream of start codon for each gene (Supplementary Table 1). 
The synthesized engineered nuclease mRNAs and/or gRNAs targeting each gene were directly microinjected 
into the murine one-cell embryos. The pups were selected based on sequencing analysis for the target region 
and PTC prediction for the mutant sequences (Supplementary Tables 2 and 3). The selected mutations intro-
duced the PTCs within the ORFs of each target gene. The mice with such mutations are typically considered as 
knockout mice for the specific gene due to the loss of functional target proteins. However, we hypothesized that 
PTC-containing mRNAs would not be completely eliminated by the NMD pathway in the mice, and therefore, 
evaluated the mRNA expression of each target gene in various tissues of homozygous mutant mice obtained by 
heterozygous intercrosses. We found that the mRNA expression of the target genes was not completely eliminated 
in various tissues of most mutant mice, which was more than what we expected. The ratios (KO/WT) of mutant 
mRNA in mutant mice to wild-type (WT) mRNA expressed in each detectable tissues of WT mice were high 
(>0.5) in twelve different strains for nine genes (Cd47, Lxrb, Rtp4, p53, p27, p16, Creb3, p19, and Ciita) (Fig. 1 and 
Supplementary Fig. 1). The NMD efficiency is diverse across different tissues. In some cases, the levels of mutant 
mRNA expression are more increased in mutant mice than in WT mice. In contrast to the other twelve mutant 
mice, the four mutant mice for Il2rg, Lepr, Reep5, and Lxra showed dramatically reduced mRNA expressions 
(Fig. 1 and Supplementary Fig. 1). These results suggest that even though the efficiency of NMD is variable, it can 
be improved by the application of specific targeting rules in the engineered nuclease-mediated indel mutations 
resulting in loss of gene function.
Mutant p53 mRNAs are frequently expressed in the p53 mutant mice created by the engi-
neered nucleases. Among the mutant mice that were created, p53 mutant mice (B6J) with a single nucle-
otide deletion in the second exon of p53 gene had the longest distance from the start codon to the PTC (Fig. 2a 
and Supplementary Table 3). Hence, these mice were selected for further experiments as detection of the result-
ing mutant protein was comparatively easier. The tumor suppressor protein p53 is critical for maintaining the 
Figure 1. The mutant/WT ratios of the mRNA expression levels for each target gene in sixteen mutant mouse 
strains carrying frameshift mutations. Gene expression in different tissues of each mouse was determined using 
quantitative PCR (qPCR). Each closed black circles represents the target gene expression in mutant mice relative 
to that in WT mice in the tissues that were tested. The closed red circles indicate that the expression of target 
gene in mutant mice is less than 20% relative to that in WT mice. The X-axis is ordered from the shortest to the 
longest distance from ATG of each target gene to their indel. The middle horizontal lines in each gene of the 
whisker plot represent the median gene expression ratios. The dotted black line indicates 50% mutant/WT ratio, 
and the dotted red line indicates 20% mutant/WT ratio.
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genomic stability in multicellular organisms; its expression is therefore induced in response to DNA damage. As 
observed in Western blotting analysis, the induction of p53 protein expression by exposure to 10 J/m2 UVC was 
not detected in the embryonic fibroblasts of p53 mutant mouse (mutant MEFs) (Fig. 2b). This result indicates that 
p53 mutant mice were successfully generated by simple genome editing. However, as observed in RNA expression 
analysis, these mice expressed p53 mRNA frequently in most of the tissues that we tested (Fig. 2c). In addition, 
their expression levels were similar to their WT littermate, except in the lungs and the kidneys. In consistence 
with a previous report13, the efficiency of NMD varied between different tissues as the mRNA level was decreased 
dramatically in the kidneys, while it was increased in the lungs (Fig. 2c). Since the mutant gene expression is 
often avoided by in vivo mechanisms such as alternative splicing14–16, we questioned if the expression of mutant 
p53 can be bypassed by alternative splicing such as nonsense-associated exon skipping. Therefore, we cloned and 
sequenced the cDNA from a full-length p53 mRNA which was not degraded but expressed in the p53 mutant 
mice and confirmed that the RNA contained a single nucleotide excision (c.54_54del1) as expected from genomic 
DNA sequencing (Supplementary Fig. 2). No product of alternative splicing generated by PTC-mediated exon 
skipping was found under the conditions we tested. The p53 mutant mice exhibited a similar tumor profile as 
ESC-based p53 KO mice reported previously17,18; however, the brain tumors that were previously observed only 
in heterozygotes of ESC-based p53 KO mice were observed in our homozygous p53 mutant mice (2 out of 21 mice 
with tumor) (Supplementary Table 5). Furthermore, the mutant p53 mRNA was frequently detected in the brain 
of p53 mutant mice with astrocytoma by in situ hybridization (Fig. 3a). This result indicates that the mutant p53 
mRNA can be translated, though its products may be unstable, non-functional, truncated, or a gain of function 
mutant p53 protein.
Mutant p53 protein is identified in p53 homozygous mutant mice. The mutation in our p53 mutant mice 
induced the frameshift from the 18th amino acid of the p53 ORF and the premature termination codon was introduced 
at the 165th amino acid (495th nucleotide) of the frameshifted p53 ORF (Supplementary Figs. 2 and 3). Thus, the com-
mercial antibody that we used for detection of wild-type p53 is not supposed to detect mutant p53 protein due to the 
alteration in the epitopes caused by frameshift mutation. To determine whether the mutant mRNA expressed in the p53 
mutant mice can indeed produce aberrant proteins, we produced an antibody for the mutant p53 protein. The mutant 
p53 antibody could detect the cloned mutant p53 protein overexpressed in 293 T cells (Supplementary Fig. 4). The 
expression of mutant p53 protein induced by UVC in homozygous mutant MEFs was also analysed to confirm it as the 
expected mutant protein by LC-MS/MS analyses (Supplementary Fig. 5). Furthermore, the p53 mutant protein, which 
was not detected in the brain of WT mice, was detected in the brain tumor mass of the p53 mutant mice by immuno-
histochemistry, using the antibody against the mutant p53 protein (Fig. 3b). Although it is not yet clear whether the 
mutant p53 proteins can cause brain tumors, these results demonstrate that the mutant proteins can be translated from 
the mutant mRNAs escaping NMD in the tissues of mutant mice.
Figure 2. p53 mRNA expression in the p53 mutant mice created by engineered nucleases. (a) Targeting strategy 
using a pair of TALENs on the p53 gene. Targeting loci of two different TALENs are indicated with red arrows 
on exon 2 of the p53 gene with their sequences also shown in red, determined by Sanger sequencing of PCR 
products from WT and p53 mutant mice. The dash (-) denotes a deleted nucleotide; Δ1 denotes the number of 
deleted nucleotide(s), aa represents amino acid. (b, c) Expression of protein or mRNA encoding p53 in mutant 
(Mu) MEFs induced upon exposure to 10 J/m2 UV treatment, determined by Western blot analysis and qPCR, 
respectively. Actin was used as an internal control. The qPCR experiments were performed in triplicates, and 
error bars indicate means ± standard deviation (SD). Full-length blots are depicted in Supplementary Fig. 6.
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NMD efficiency is dependent on the position of the target site in the gene. Since the diverse 
genomic profiles of the sixteen mutant mice allowed us to examine the efficiency of NMD in vivo, we attempted to 
find an effective approach to improve the NMD efficacy and the mutant mRNA clearance yield induced by sim-
ple targeting using engineered nucleases. We analyzed the property of genetic mutation for each mutant mouse 
and compared its mRNA expression (Supplementary Table 3). There are variations in mutant mRNA clearance 
depending on the target position. In contrast to what is previously known, the elimination of mutant mRNAs was 
less effective in the mutant mice targeting exon with a start codon than in the mutant mice targeting the exons 
that are downstream of exons with a start codon. The ratios (KO/WT) reflecting NMD levels were less than 50% 
in all eleven mice targeting the exon with start codon, but 80% or more in four out of five mutant mice targeting 
Figure 3. Expression of mutant p53 mRNA and protein in the brain of WT and p53 mutant mice. (a) p53 
mRNA in astrocytoma in situ in p53 mutant mouse. DIG-labelled cRNA of p53 displayed the p53 mRNA 
expression in both WT and p53 mutant mice bearing astrocytoma in the brain. (b) Mutant p53 protein in the 
brain of p53 mutant mouse. Mutant p53 protein was detected in the brain and brain tumor of p53 mutant mice, 
whereas the expression of mutant p53 was not confirmed in the brain of WT mice by immunohistochemistry 
using antibody against the mutant p53 protein. The enlarged parts of the dotted rectangle appear on the right 
panel.
5Scientific RepoRtS |         (2020) 10:4173  | https://doi.org/10.1038/s41598-020-61154-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
the downstream exons (Fig. 1). In greater depth, in the eleven strains targeting the exons with start codon, the 
target sites were located in the regions close to the translation initiation sites (within approximately 100 bp down-
stream of ATG) in the common first coding exons transcribed by all known mRNA isoforms (Supplementary 
Table 3). In five genes, the target sites were located at a distance farther than approximately 100 bp away from the 
start codons, thereby avoiding the exons with start codon (Supplementary Table 3). All single gRNAs induced 
small deletions (indel size) within 50 bp in length, except for p27 in which 86 bp was deleted. The indel-mediated 
PTCs were generated within approximately 100 bp downstream from the deletion sites (distance from indels to 
PTC), except in p53 and Lxra. As a result, the mutant mRNAs were more frequently detected in the mice where 
the target sites were in close proximity to ATG (<110 bp) in the genes of interest than in those where the target 
sites were located far away from ATG (>110 bp, Median KO/WT ratios of mRNAs: 66% vs. 21% (proximity 
vs. far), p = 0.0007, two-tailed Mann–Whitney test, Fig. 4a and Supplementary Table 3). Specifically, the abun-
dance of mRNA in Il2rg, Lepr, Reep5 and, Lxra mutant mice was remarkably reduced by over 80% as compared 
to those in their WT controls of all mouse strains, except in the colon tissue of Lxrα mutant mice (Fig. 1 and 
Supplementary Fig. 1). We also found that the expression of mutant mRNAs was significantly decreased when 
the PTCs were located farther than 150 bp away from ATG in its mRNA sequences (50% vs. 68% median KO/WT 
ratio for PTCs over 150 bp vs. within 150 bp from ATG, p = 0.0019; Fig. 4b). The lengths of the deleted regions 
(indel size) and the distance from PTC to EJC did not have an effect on mutant mRNA clearance (Fig. 4c, d and 
Supplementary Table 3). We could not find any rule in the number of EJCs (exon-exon junctions between PTCs 
and the last exons) bound to PTC-harboring mRNAs. There was no difference in the genetic backgrounds of the 
mice (FVB/N and C57BL/6 in p16, p19, and p53; Fig. 1). Taken together, these results suggest that targeting the 
exons, which are downstream of the exons with start codons or distant from ATG, is effective for complete induc-
tion of NMD processes in vivo via engineered nucleases.
Discussion
In this study, we aimed to determine the validity of mutant mice developed using the TALEN or CRISPR/Cas9 
system by examining the NMD efficiency for PTC-containing mRNAs in vivo. However, these results ultimately 
indicated that the previous strategy to induce the PTC-mediated loss of gene function could be incomplete. 
The PTC-containing mRNAs might be protected from NMD in all of our mutant mice that were produced by 
introducing PTCs in proximity to the translation initiation site. It is possibly due to the unusual translation that 
allows ribosomes to reinitiate translation at the downstream AUG codons rather than at the first AUG codon19,20. 
The reinitiation of NMD-resistant transcripts could in turn lead to the expression of aberrant proteins retaining 
deleterious gain-of-functions, followed by the development of nonsense mutation-mediated diseases and misin-
terpretation of their phenotypes in the frameshifted mutant mice. Furthermore, our results as well as previous 
studies have shown that NMD efficiency is diversely modulated by cell types, cellular signalling, and stresses, 
which might obscure its ability to eliminate mRNAs (Fig. 1)21,22. In addition, several recent studies show that 
CRISPR-induced PTCs are also linked to alternative splicing and/or exon skipping to remove the exons with 
PTCs in the transcripts14,15,21–23. Accordingly, aberrant mRNAs could be maintained by either NMD-escaping 
or exon skipping at the exon with PTC. Thus the mutant mRNA detected in mice may mitigate the expected 
loss-of-function and the phenotypes of mutant mice. These results indicate that the use of the engineered nucle-
ases to introduce PTCs in genes will pose new challenges in the field of genome editing including CRISPR based 
editors.
Most previous studies using engineered nucleases to produce knockout mice have targeted the regions 
close to a translation initiation site (ATG) or the first coding exons transcribed into all known mRNA isoforms 
(Supplementary Table 4)5. As a result, the PTCs were generated an average of 76 bp away from the deletion sites. 
According to our findings, targeting the regions close to the AUG codons is likely to cause the mRNAs contain-
ing PTCs to escape the NMD. Thus, the mutant RNAs may be translated to produce truncated or frameshifted 
proteins with deleterious gain-of-function9,24,25, thereby obscuring the phenotypic study of mutant mice created 
using the engineered nucleases. However, the expression of virtually all of the corresponding mRNAs has not 
been examined in many previous studies (Supplementary Table 4). One limitation of our study was that we could 
not detect the mutant proteins except for p53 due to the lack of antibodies against them. Further studies on del-
eterious gain-of-function for each mutant protein in various mutant mice are required to improve our findings. 
Nevertheless, the results now suggest that the measurement of aberrant mRNAs in the mutant mice created using 
the engineered nucleases will allow us to obtain more clear information in terms of phenotypic interpretation. 
Furthermore, by determining a better target position to avoid the first exons, the NMD can be induced efficiently 
to eliminate the mutant mRNAs expressed by the targeted alleles. Targeting the exons that are downstream of the 
exons with start codons or distant from ATG will improve the efficiency of the NMD process in vivo. In addition, 
we are also concerned about the possibility of nonsense-associated exon skipping (NAS). Similarly to the NMD, 
the NAS is bypassed when PTCs emerge at the first and last exons, but mainly appears when the exons carrying 
PTCs are in frame14,15. Although we could not confirm directly, we took separate steps from four mutant lines 
with reduced mRNA to prevent misinterpretation by the NAS. The primers were designed to avoid binding to 
the exons containing PTCs to prevent misinterpretation of the reduced signals. As a result, no exon skipping was 
found in these mutant mice. Taken together, inducing PTCs in the out-frame exon (except the first exon) poten-
tially prevents aberrant protein expression by reducing exon skipping and promoting NMD.
The diverse rules and variable efficiency of NMD have also been observed in human cancers26. Since the effi-
cacy of NMD is often associated with symptoms of diseases caused by mutations inducing addition of PTCs, dif-
ferent tumor spectrums are observed, for example, in the cancer patients with different mutations24,27. Therefore, 
the translation of mutant RNAs may affect the tumorigenic phenotypes of p53 mutant mice by causing deleterious 
gain-of-function in the frameshifted mutant protein. However, there were no frameshift mutant p53 mice models 
to mimic human patients. These types of models can be applied as new experimental models to study the cancer 
6Scientific RepoRtS |         (2020) 10:4173  | https://doi.org/10.1038/s41598-020-61154-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
with genetic variation caused by indel mutations. Consequently, the residual mRNAs resulting from NMD bypass 
or exon skipping can cause unexpected problems in analyses and interpretation; for example, in the clinical trials 
using the CRISPR/Cas9 system to disrupt genes in patients. Along with the off-target effects of using the CRISPR/
Cas9 system that have garnered great attention, incomplete RNA decay should also be one of the major concerns 
that needs to be accounted for when applying engineered nucleases in general gene function studies. When only 
one gRNA can be used in the clinic, the key step for success would lie in the efficiency of the specific gRNA that 
causes the loss of function of a gene. Therefore, investigators should put in more efforts into analyzing the status of 
NMD bypass and/or exon skipping in their trials, not only at the DNA level but also at the RNA and protein levels, 
to validate the lack of expression of non-natural RNAs and proteins. Thus, we believe that the findings from this 
study will provide a new important perspective in the field of targeted genome editing using engineered nucleases.
Figure 4. Target regions and distances from ATG codon to the PTC influence the efficiency of mutant mRNA 
decay (mutant mRNA levels/WT mRNA levels). The Mu/WT ratios of mRNA expression levels for target gene 
in each tissue are shown. (a) The efficiencies of mRNA decay are differentially influenced by the target regions: 
Proximity to ATG (<110 bp), far from ATG (>110 bp). (b) The influence of distance from the ATG codon to 
the PTC on the efficiency of mRNA decay. PTCs are located within 150 bp downstream from ATG (<150) or 
at distance of over 150 bp from ATG (>150). (c) The influence of the number of deleted nucleotides on the 
efficiency of mRNA decay. The Mu/WT ratios of mRNA expression levels for the target genes in each tissue 
are shown for each range of deletion lengths. Deletion lengths are less than 10 bp (<10 bp), from 10 to 30 bp 
(10~30), or over 30 bp (>30). (d) The distance from the PTC to the next EJC influences the efficiency of mRNA 
decay. PTCs are located within 100 bp upstream from the next EJC (<100) or at a distance of over 100 bp from 
the next EJC (>100). The central lines represent the median gene expression ratio. p values are from two-tail 
Mann-Whitney tests. Mu, Mutant.
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Methods
preparation of CRISPR/Cas9 and TALEN mRnAs. Cas9 and TALEN mRNAs were prepared using the 
mMESSAGE mMACHINE T7 Ultra kit (Ambion), and sgRNAs were synthesized from PCR-driven templates 
using the MEGA shortscript T7 kit (Ambion) following the manufacturer’s instructions. Each mRNA was diluted 
in diethyl pyrocarbonate (Sigma, St. Louis, MO, USA)-treated injection buffer (0.25 mM EDTA, 10 mM Tris, 
pH 7.4) to the working concentrations. Plasmids encoding Cas9 and TALEN were obtained from ToolGen, Inc. 
(Republic of Korea). The target sequences of TALENs and sequences of sgRNAs for each target gene in are dis-
played in Supplementary Table 1.
Animals. All animal experiments were performed in accordance with the Korean Food and Drug 
Administration (KFDA) guidelines. Experimental protocols were reviewed and approved by the Institutional 
Animal Care and Use Committee (IACUC) of the Laboratory Animal Research Center at Yonsei University 
(Permit Number: 201506-322-02). Mice were maintained in the specific pathogen-free (SPF) facility of the Yonsei 
Laboratory Animal Research Center.
Microinjection into mouse embryos. C57BL/6JBomTac and FVB/NTac mouse strains were used as 
embryo donors. The superovulation was induced by intra-peritoneal injections of 5 IU pregnant mare serum 
gonadotropin (Sigma) and 5 IU human chorionic gonadotropin (Sigma) at 48 hr intervals in 6–8-weeks-old 
female mice. The superovulated female mice were mated with stud males, and fertilized embryos were col-
lected from the oviducts. For the generation of endonuclease-mediated mutants, microinjection of fertilized 
zygotes was performed as previously described3,4. In brief, endonucleases were injected into the cytoplasm of 
one-cell embryos using a piezo-driven manipulator (Prime Tech. Ltd., Japan), followed by transfer into the ovi-
ducts of ICR pseudo-pregnant foster mothers to produce live mice. For TALEN, 50 ng/μL of TALEN mRNA was 
intra-cytoplasmically injected into the mouse embryos. For CRISPR/Cas9, 20 ng/μL of Cas9 mRNA and 100 ng/
μL of sgRNA were mixed and injected into the cytoplasm of one-cell stage embryos.
Genotyping and sequence analyses. To screen founder mice with endonuclease-mediated mutations, 
polyacrylamide gel electrophoresis (PAGE)-based assays were performed as previously described28 using genomic 
DNA samples from tail biopsies. In brief, the genomic region encompassing the endonuclease target site was 
PCR-amplified, melted, and re-annealed to form heteroduplex DNA, and loaded and analyzed by acrylamide gel 
electrophoresis. For sequence analysis, the PCR products from the founder mice were cloned using T-Blunt PCR 
Cloning Kit (SolGent Co., Ltd. Korea), and the mutations were identified by direct sequencing analysis (Cosmo 
Biotech Co., Ltd. Korea). To confirm the germ-line transmission of mutations, all the mutant sequences were also 
validated in the offspring derived from each founder. The homozygous mutant mice generated by interbreeding 
heterozygotes were screened by PAGE- or PCR-based genotyping methods with primer pair that distinguishes 
WT and mutant allele (Supplementary Table 6).
RT-PCR and qPCR. Total RNAs from the cells and tissues of each mutant mouse were prepared with Trizol 
reagent (Invitrogen, Carlsbad, CA, USA), and 1 μg of total RNA was reverse-transcribed to produce cDNA using 
Superscript III First-Strand Synthesis System with oligo-dT primers (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s procedures. PCR was performed with Master preMix (Super Bio Co., Korea) on the 
MyCycler Thermal Cycler (Bio-Rad, Hercules, CA, USA). Quantitative analysis of gene expression was performed 
using SYBR Green SuperMix (Bio-Rad) on the CFX connect Real-Time System (Bio-Rad), with each sample 
measured in triplicates. The relative gene expression values were calculated using the CFX manager software 
(Bio-Rad) after normalization to the expression levels of actin, Gapdh, or Hprt. Means ± standard deviations 
were obtained from triplicate experiments. The primer pairs used in these assays are listed in the Supplementary 
Table 7.
Western blotting. To analyze the p53 protein expression, cells were suspended in lysis buffer (50 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, 20 mM EDTA, 0.2% NP-40, and protease inhibitors (GenDEPOT, TX, USA). 
The protein lysates were analyzed by immunoblotting with antibodies specific for p53 (sc-99 and sc-6243, Santa 
Cruz Biotech, Santa Cruz, CA, USA), and ACTIN (Sigma). The epitopes of polyclonal or monoclonal antibody 
for p53 are mapped within amino acids 1–393 (FL-393) or 14–389 (Pab240) of human origin p53 protein. The 
anti-mutant p53 polyclonal antibody was generated by AbFrontier (Seoul, Republic of Korea) using the peptide 
SAPWPSTRSHST, corresponding to the C-terminus of the frameshifted mutant p53 protein (Supplementary 
Fig. 4).
In situ hybridiation (iSH). Full-length p53 sequences derived from a pEGFP-C2 p53 plasmid were used 
to synthesize the complementary RNA (cRNA) probes for p53. The plasmid was digested with restriction 
enzymes, and then labeled with Digoxigenin (DIG) by in vitro transcription using the RNA labeling kit (Roche 
Diagnostics, Indianapolis, IN, USA). Four-micrometer sections obtained from paraformaldehyde-fixed and 
paraffin-embedded tissue samples were deparaffinised, rehydrated, and incubated with 0.5% acetic anhydride 
solution to remove nonspecific binding. Hybridization was performed with DIG-sense and -antisense cRNA 
probes in 20× SSC solution containing 50% formamide at 42 °C overnight. The next day, the slides were washed 
in the SSC solution at 50 °C and incubated with an anti-DIG Fab antibody (Roche Diagnostics) conjugated to 
alkaline phosphatase (AP), at 4 °C overnight. To detect alkaline phosphatase, nitro blue tetrazolium/5-bromo-
4-chloro-3-indolyl phosphate (NBT/BCIP, Roche Diagnostics) was added. Nuclei were counterstained with 
Nuclear Fast Red (Vector Laboratories, Inc., Burlingame, CA, USA).
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immunohistochemistry (iHc). IHC was performed as described previously29 with minor modification. 
Briefly, slides were deparaffinised and rehydrated through series of graded ethanol solutions. Antigen retrieval 
was performed using a pressure cooker. The endogenous peroxidase activity was blocked by incubating the slides 
with 3% H2O2 for 30 min followed by incubation with protein blocking solution (Dako, Glostrup, Denmark) 
for 1 hr at room temperature. Next, the slides were at first incubated with the mutant p53 antibody in a humid 
chamber at 4 °C overnight, and were then incubated with the secondary rabbit IgG (Dako) antibody for 15 min-
utes at room temperature, and developed with Dako Envision+ System-HRP DAB (Dako). After counterstain-
ing with Meyer’s Hematoxylin (Sigma-Aldrich), the slides were mounted with the mounting solution (Electron 
Microscopy Sciences, Hatfield, PA, USA).
Data availability
No datasets were generated or analyzed during the current study.
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